Krystal Biotech
Manufacturing · Pennsylvania, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
2100 Wharton St Ste 701, Pittsburgh, Pen...Phone Number
(412) 586-5830Website
www.krystalbio.comRevenue
$440.5 MillionStock Symbol
KRYSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Krystal Biotech
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in PittsRead more
Krystal Biotech Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Krystal Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Krystal Biotech has new funding data
Earning: See what the market has to say on Krystal Biotech recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Krystal Biotech launches new products
Check if Krystal Biotech has recently received funding, and reach out quickly before it becomes old news!
Check out if Krystal Biotech is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Krystal Biotech
Krystal Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Krystal Biotech had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Krystal Biotech as Masked Content
Find 3 more new buyers
Compare Similar Companies to Krystal Biotech
Compare insights from companies similar to Krystal Biotech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$15.5M
51-200
Private
$31M
2003
JH
Jim HavilandVice President, Quality Assurance, Regulatory Compliance & Regulatory Affairs
Company Profile Activity
Activity Insights
Krystal Biotech is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Krystal Biotech is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Krystal Biotech.
Krystal Biotech Tech Stack
A closer look at the technologies used by Krystal Biotech
Most Recent Scoops
Event
had a presence at the 3rd World Congress on Rare Skin Diseases in France in July, including hosting a well-attended symposium focused on the dystrophic epidermolysis bullosa community.
Event
partnered with DEBRA of America to host a virtual education webinar during Q2 2026, focused on recent VYJUVEK label updates and practical bandaging techniques, attracting more than 100 live attendees.
Partnership, Training, Learning & Development, Medical Education & Training
Project
Krystal Biotech is working closely with treatment centers in France to facilitate access and treatment continuity for VYJUVEK, which is available through the early access pathway, while exploring solutions to support home administration given the product's current GMO classification requirements.
Pharmaceuticals
Earnings
Krystal Biotech has reported net income of $54.8 million, or $1.85 per basic share and $1.79 per diluted share, for Q2 2026, representing an increase compared to net income of $38.3 million, or $1.33 per basic share and $1.29 per diluted share, in Q2 2025.
Earnings, Finance
Project
Pharmaceuticals, Clinical Operations
Krystal Biotech News & Media
Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More
Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks, bonds, oil, and crypto all at once.Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launchThese 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead
They are riding strong tailwinds that could lift them higher.Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its second quarter 2026 financial results on Monday, August 3, 2026, prior to the open of U.S. markets.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Krystal Biotech
Sign Up For FreeTo access detailed company insights
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Ph... Read More
